GSK plc (LON:GSK – Get Free Report) insider Emma Walmsley sold 38,459 shares of the stock in a transaction dated Monday, February 17th. The stock was sold at an average price of GBX 1,418 ($17.92), ...

GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...

Prime Video’s ‘Beast Games’ pushes its contestants to their limits mentally, physically, and emotionally. In the first season, Emma Nelson decided to test her abilities in the intense competition and ...

GSK (GSK), a large British drug maker, is rallying 8% after reporting higher-than-expected fourth-quarter earnings per share and raising its long-term revenue guidance. GSK's Beat-and-Raise ...

CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...

Dame Emma Walmsley Thanks Julie. so in summary, GSK is powering forward. This comes on the back of a strong track record of operational delivery and accelerating progress in innovation and ...

GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments. The British pharmaceutical giant said Wednesday that the 2.0 billion ...

GSK is prioritizing development of its hepatitis ... to discuss her company's fourth-quarter and full-year earnings, CEO Emma Walmsley said that when it came to the British pharma’s infectious ...

GSK also has no or minimal exposure to any potential US trade tariffs on Mexico, China and Canada, Chief Executive Officer Emma Walmsley said on a call with reporters on Wednesday. Tariffs are ...

Chief executive Emma Walmsley said: “GSK delivered another year of excellent performance in 2024, with strong sales and core profit growth driven by accelerating momentum of our specialty medicines ...

GSK's shares were up 6% at 1342 GMT after the British drugmaker's fourth-quarter results also topped expectations. Since taking the helm in 2017, CEO Emma Walmsley has returned GSK to growth with ...